The metabolic and mitogenic properties of basal insulin analogues. (February 2013)

• Record Type: Journal Article
• Authors: Tennagels, Norbert; Werner, Ulrich
• Is Part Of: Archives of physiology and biochemistry. Volume 119:Number 1(2013)
• Page Start: 1
• Page End: 14
• Publication Date: 2013-02
• Subjects: Physiology -- Periodicals; Biochemistry -- Periodicals; Biophysics -- Periodicals; Biochemistry; Physiology; 571
• DOI: 10.3109/13813455.2012.754474
• Languages: English
• ISSNs: 1381-3455

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <italic>Context</italic>: Retrospective, observational studies have reported an association between diabetes treatment with insulin and a higher incidence of cancer.</p> <p> <italic>Objective</italic>: Overview the literature for <italic>in vitro</italic> and <italic>in vivo</italic> studies of the metabolic and mitogenic properties of basal insulin analogues and assess the implications for clinical use.</p> <p> <italic>Methods</italic>: Relevant studies were identified through PubMed and congress abstract database searches; data on metabolic and mitogenic signalling in relation to insulin treatment of diabetes are included in this review.</p> <p> <italic>Results</italic>: The balance of evidence shows that although some analogues have demonstrated mitogenic potency in some <italic>in vitro</italic> studies in cancer cell lines, these findings do not translate to the <italic>in vivo</italic> setting in animals or to the clinical setting in humans.</p> <p> <italic>Conclusions</italic>: The current consensus is that there is no clinical or <italic>in vivo</italic> evidence to indicate that any commercially available insulin analogue has carcinogenic effects. Large-scale, prospective clinical and observational studies will further establish any potential link.</p> </abstract>